Welcome to our dedicated page for Benitec Biopharm news (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharm stock.
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage, gene therapy-focused biotechnology company developing novel genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference (ddRNAi) platform. News related to Benitec centers on the progress of its lead program, BB-301, a Silence and Replace-based gene therapy candidate in clinical development for dysphagia associated with Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life‑threatening genetic disorder.
Investors following BNTC news can expect detailed updates on clinical trial milestones from the ongoing Phase 1b/2a study of BB-301 (NCT06185673). Company press releases have highlighted interim data showing that all six patients in Cohort 1 met formal statistical criteria for response, with significant and sustained improvements across multiple measures of swallowing function and dysphagic symptom burden. Longer-term follow-up reports describe durable and deepening improvements at 24 months post-treatment for the first treated patient.
Benitec’s news flow also includes regulatory developments, such as the FDA’s Fast Track Designation for BB-301 and Orphan Drug Designations from both the FDA and EMA, as well as updates on interactions with the FDA regarding pivotal study design. In addition, the company regularly reports financial results in Forms 10‑Q and 10‑K, accompanied by press releases that discuss research and development spending, cash position, and capital-raising activities, including underwritten offerings and registered direct offerings of common stock.
Corporate governance and leadership items, such as the appointment of new board members with biotechnology and pharmaceutical experience, are also disclosed through Benitec’s news releases and related Form 8‑K filings. For investors and observers, the BNTC news page provides a centralized view of clinical data updates, regulatory designations, financing transactions, and corporate developments that shape the company’s progress as a clinical-stage gene therapy developer.
Benitec Biopharma (NASDAQ: BNTC) reported positive interim results from the BB-301 Phase 1b/2a trial and said the FDA granted Fast Track designation for BB-301 for treatment of OPMD with dysphagia. All six patients in Cohort 1 met the formal statistical criteria for response (a 100% response rate).
Cohort 1 showed sustained improvements in dysphagic symptom burden, post-swallow residue, timed drinking capacity, and pharyngeal closure. BB-301 has prior Orphan Drug designations from both FDA and EMA. First patient in Cohort 2 was treated in Q4 2025. Benitec plans an FDA meeting in 2026 to confirm pivotal study design.
Benitec Biopharma (NASDAQ: BNTC) appointed Dr. Sharon Mates to its board of directors, effective November 2, 2025. Dr. Mates previously co-founded and served as CEO and chairman of Intra‑Cellular Therapies from 2002 until its ~$14.6 billion acquisition by Johnson & Johnson in 2025. She led development efforts that included FDA approval of CAPLYTA in 2019. Benitec said her experience will support progression of its BB‑301 OPMD program and broader development of its ddRNAi platform.
Benitec Biopharma (NASDAQ: BNTC) will provide a clinical update on BB-301, its gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD).
The company said it will report results for the six patients treated in Cohort 1 of the Phase 1b/2a study and host an investor webcast on November 3, 2025 at 8:00 am EST.
Webcast registration was posted by the company for investor access to the update.
Benitec Biopharma (NASDAQ: BNTC) released its full year 2025 financial results and provided updates on its BB-301 clinical program for OPMD treatment. The company reported a net loss of $37.9 million ($1.05 per share) compared to $22.4 million in 2024. Total expenses increased to $41.8 million, with R&D expenses at $18.3 million and G&A expenses at $23.4 million.
Key operational highlights include a favorable DSMB recommendation to continue enrollment into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study, expected to begin in Q4 2025. The company maintains a strong financial position with $97.7 million in cash and cash equivalents as of June 30, 2025. Interim clinical results for Cohort 1 are anticipated in Q4 2025.
Benitec Biopharma (NASDAQ: BNTC) has announced significant progress in its Phase 1b/2a Clinical Treatment Study for BB-301, its gene therapy treatment. The company successfully completed treatment of the sixth and final subject in Cohort 1 with a low dose of BB-301 in April 2025.
The Independent Data Safety Monitoring Board (DSMB) has completed its review of all six subjects in Cohort 1 and recommended continuation of subject enrollment. Following this positive recommendation, enrollment for Cohort 2 is expected to begin in Q4 2025. The company reports encouraging results regarding BB-301's safety profile, particularly noting the benefits of their local direct intramuscular delivery method.
Benitec Biopharma (Nasdaq: BNTC) has announced the pricing of a combined stock offering expected to raise $30 million in gross proceeds. The offering consists of:
- An underwritten offering of 1,443,000 common stock shares (or pre-funded warrants)
- A concurrent registered direct offering of 900,000 shares with Suvretta Capital
Each share is priced at $13.00, while pre-funded warrants are priced at $12.9999 with a $0.0001 exercise price. The offerings are expected to close on March 26, 2025. The company plans to use the proceeds for product candidate development, working capital, and general corporate purposes. Leerink Partners and TD Cowen are serving as bookrunning managers, with Citizens Capital Markets as lead manager.
Benitec Biopharma (NASDAQ: BNTC) has reported positive interim clinical results from its Phase 1b/2a study of BB-301 gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). Three subjects treated with BB-301 showed significant improvements in swallowing function:
- Subject 1 achieved durable improvements 12 months post-treatment with 37% reduction for thin liquid, 18% for solid food, and 29% for thick liquids in swallowing efficiency
- Subject 2 reached a clinically normal swallowing profile at 12 months with 91% symptom reduction
- Subject 3 achieved a clinically normal swallowing profile at 3 months with 68% symptom reduction
The study has treated five subjects safely with the low-dose BB-301, with the sixth and final subject of Cohort 1 expected to receive treatment in Q2 2025. No severe adverse events have been reported. Results will be presented at the 2025 Muscular Dystrophy Association Conference in Dallas.
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced its participation in three major healthcare conferences in March 2025.
The company will present at:
- TD Cowen 45th Annual Health Care Conference on March 5, 2025 (9:50-10:20 AM EST)
- Leerink Partners Global Healthcare Conference on March 12, 2025 (9:20-9:50 AM EST)
- 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, TX, featuring two sessions on March 18-19, 2025, focusing on Oculopharyngeal Muscular Dystrophy and Clinical Trial Updates
All presentations will be available via live webcast, and one-on-one meetings can be scheduled with management.
Benitec Biopharma (NASDAQ: BNTC) has released its Q2 2025 financial results and provided updates on its BB-301 Phase 1b/2a clinical trial for Oculopharyngeal Muscular Dystrophy (OPMD). The fifth subject was safely treated in February 2025, with interim results showing durable, clinically meaningful improvements in swallowing function for the first subjects treated.
Financial highlights for Q2 2025 include:
- Revenue: $0.0 million
- Total expenses: $8.6 million (up from $6.9 million in Q2 2024)
- Net loss: $7.4 million, or ($0.33) per share
- Cash position: $78.3 million as of December 31, 2024
The company plans to begin treating a second cohort with a higher dose of BB-301 later in the year. An interim clinical study update will be presented at the 2025 Muscular Dystrophy Association Conference on March 19, 2025.